BMEA

SEC source: 0000950170-24-000956 · ownership.xml · nonDerivative · entry 2

Erdtmann Rainer M · CIK 0001455767 · Director · President and COO

10b5-1 filing: No plan indicated

Ownership: Indirect · By daughter

Disclosed balance after: 9,400

SEC source: 0000950170-24-000956 · ownership.xml · nonDerivative · entry 1

Erdtmann Rainer M · CIK 0001455767 · Director · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 731,027

F1 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000950170-23-067424 · ownership.xml · nonDerivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,543

F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022.

SEC source: 0000950170-23-046099 · ownership.xml · derivative · entry 1

Frias Juan Pablo · CIK 0001990665 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-08-30

F1 · derivative.exercise_date: One-sixteenth (1/16th) of the total number of shares subject to the stock option shall vest and become exercisable at the end of the third month following August 31, 2023 and one-sixteenth (1/16th) of the total number of shares subject to the stock option shall vest and become exercisable quarterly thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000929638-23-001746 · form4.xml · derivative · entry 4

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,989

Underlying: Common Stock · 6,989 shares

Expires 2033-06-13

F5 · derivative.exercise_date: The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to Ms. Chen's continuing service to the Issuer through such vesting date.

F4 · ownership.direct: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.

SEC source: 0000950170-23-028668 · ownership.xml · derivative · entry 1

AGUIAR ERIC · CIK 0001262325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,989

Underlying: Common Stock · 6,989 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000950170-23-028671 · ownership.xml · derivative · entry 1

Faust Elizabeth · CIK 0001572143 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,989

Underlying: Common Stock · 6,989 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000950170-23-028670 · ownership.xml · derivative · entry 1

Ray Sumita · CIK 0001579629 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,989

Underlying: Common Stock · 6,989 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000950170-23-028679 · ownership.xml · derivative · entry 1

Hitchcock Michael J.M. · CIK 0001856674 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,989

Underlying: Common Stock · 6,989 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0001859061-23-000007 · primary_doc.xml · nonDerivative · entry 2

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,500,000

F2 · price: A total of 50,000 shares were sold at an average price of 34.5633 in multiple transactions ranging from 34.50 to 35.02 Details of the specific transactions are available upon request.

SEC source: 0000950170-23-026142 · ownership.xml · nonDerivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,198

F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022.

SEC source: 0001859061-23-000007 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,550,000

F1 · price: A total of 75,000 shares were sold at an average price of 33.81 in multiple transactions ranging from 33.44 to 34.43. Details of the specific transactions are available upon request.

SEC source: 0001859061-23-000006 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,625,000

F1 · price: A total of 25,000 shares were sold at an average price of 33.84 in multiple transactions in a range of 33.50 to 34.50. Details of the specific transactions are available upon request.

SEC source: 0001859061-23-000005 · primary_doc.xml · nonDerivative · entry 2

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,650,000

F2 · price: A total of 150,000 shares were sold at an average price of 34.508 in multiple transactions in a range of 33.61 to 35.64. Details of the specific transactions are available upon request.

SEC source: 0001859061-23-000005 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,800,000

F1 · price: A total of 100,000 shares were sold at an average price of 33.9931 in multiple transactions in a range of 33.01 to 34.855. Details of the specific transactions are available upon request.

SEC source: 0001859061-23-000004 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,900,000

F1 · price: A total of 200,000 shares were sold at an average price of 29.1188 in multiple transactions in a range of 28.85 to 29.495. Details of the specific transactions are available upon request

SEC source: 0001859061-23-000003 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,100,000

F1 · price: A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64. Additional details of the individual transactions are available upon request.

SEC source: 0001859061-23-000002 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,100,000

F1 · price: A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64

SEC source: 0000929638-23-001057 · form4.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,570,872

F1 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F2 · ownership.nature: Represents (i) 1,795,928 shares of Common Stock held by the Master Fund, (ii) 1,717,232 shares of Common Stock held by Fund III, and (iii) 57,712 shares of Common Stock held by the Account.

SEC source: 0000899243-23-001486 · doc4.xml · derivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,300

Underlying: Common Stock · 126,300 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-23-001487 · doc4.xml · derivative · entry 1

Erdtmann Rainer M · CIK 0001455767 · Director · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,000

Underlying: Common Stock · 118,000 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-23-001484 · doc4.xml · derivative · entry 1

Butler Thomas Andrew · CIK 0001857171 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,350

Underlying: Common Stock · 354,350 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 10

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 734,027

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 9

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By son

Disclosed balance after: 7,000

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 8

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 804,027

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 7

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 7,000

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 6

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 808,027

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 5

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By daughter

Disclosed balance after: 6,400

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 4

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 812,027

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-22-037438 · doc4.xml · nonDerivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,925

F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022.

SEC source: 0000899243-22-036010 · doc4.xml · nonDerivative · entry 1

Hitchcock Michael J.M. · CIK 0001856674 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $7.97, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4.

SEC source: 0000899243-22-035697 · doc4.xml · nonDerivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,407

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $7.6000 to $7.6499, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4.

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 3

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,027

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001859061-22-000002 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,300,000

F1 · shares: Shares were sold in multiple transaction in a range of prices from 13.65 to 14.01 and an average price of 13.872. Details of the specific trades are available upon request

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 2

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 832,027

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001859061-22-000001 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,330,684

SEC source: 0000899243-23-004578 · doc5.xml · nonDerivative · entry 1

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 849,127

F1 · balance_after: Includes 873,068 shares received prior to the gift in a distribution-in-kind, without consideration, from Biomea Health, LLC made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: Includes 76,059 shares held directly by the Reporting Person and the remaining shares are held directly by the Reporting Person through a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001856641-22-000001 · primary_doc.xml · nonDerivative · entry 1

A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,365,342

SEC source: 0001567619-22-013359 · doc1.xml · derivative · entry 3

Chen Bihua · CIK 0001599214 · Director · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,867

Underlying: Common Stock · 23,867 shares

Expires 2032-06-21

F5 · derivative.exercise_date: The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant.

F4 · ownership.direct: Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.

SEC source: 0000899243-22-024053 · doc4.xml · derivative · entry 1

AGUIAR ERIC · CIK 0001262325 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,867

Underlying: Common Stock · 23,867 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000899243-22-024051 · doc4.xml · derivative · entry 1

Faust Elizabeth · CIK 0001572143 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,755

Underlying: Common Stock · 45,755 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The shares underlying the stock option shall vest in 36 equal monthly installments over a three year period beginning on June 22, 2022, so that all shares shall have vested on June 22, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-22-024058 · doc4.xml · derivative · entry 1

Ray Sumita · CIK 0001579629 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,867

Underlying: Common Stock · 23,867 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000899243-22-024056 · doc4.xml · derivative · entry 1

Hitchcock Michael J.M. · CIK 0001856674 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,867

Underlying: Common Stock · 23,867 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000899243-22-021082 · doc4.xml · nonDerivative · entry 1

Biomea Health, LLC · CIK 0001856675 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: On June 1, 2022, Biomea Health, LLC distributed in-kind, without consideration, in the aggregate 4,365,342 shares of the Issuer's Common Stock pro-rata to its members, in accordance with the exemption under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. No shares were sold by the members.

F1 · price: On June 1, 2022, Biomea Health, LLC distributed in-kind, without consideration, in the aggregate 4,365,342 shares of the Issuer's Common Stock pro-rata to its members, in accordance with the exemption under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. No shares were sold by the members.

F2 · ownership.nature: These shares are held directly by Biomea Health, LLC. Rainer M. Erdtmann and Thomas Butler are members of the Issuer's Board of Directors and members of the Reporting Person.

SEC source: 0000899243-22-020517 · doc4.xml · nonDerivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,307

F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the closing price of the Issuer's common stock on May 31, 2022.

SEC source: 0000899243-22-009752 · doc4.xml · derivative · entry 1

Ray Sumita · CIK 0001579629 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,461

Underlying: Common Stock · 21,461 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The shares underlying the stock option shall vest in equal monthly installments over a three year period beginning on June 16, 2021, so that all shares shall have vested on June 16, 2024, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-22-002217 · doc4.xml · nonDerivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.5550 to $8.7400, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4.

SEC source: 0001567619-21-021720 · doc1.xml · derivative · entry 1

Valle Franco · CIK 0001699848 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,770

Underlying: Common Stock · 144,770 shares

Expires 2031-12-03

F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0001567619-21-021721 · doc1.xml · derivative · entry 5

Erdtmann Rainer M · CIK 0001455767 · Director · President & COO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,490

Underlying: Common Stock · 165,490 shares

Expires 2031-12-03

F4 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0001567619-21-021722 · doc1.xml · derivative · entry 5

Butler Thomas Andrew · CIK 0001857171 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,400

Underlying: Common Stock · 305,400 shares

Expires 2031-12-03

F4 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date.